Indeed, we found that silencing LDHC sensitizes breast cancer cells to olaparib and cisplatin albeit at different extents, thereby improving the efficacy of either treatment with subtle differences in cell line sensitivity. This evidence concerns the gene LDHC and breast carcinoma.